113 related articles for article (PubMed ID: 24824310)
1. U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.
Lee HZ; Miller BW; Kwitkowski VE; Ricci S; DelValle P; Saber H; Grillo J; Bullock J; Florian J; Mehrotra N; Ko CW; Nie L; Shapiro M; Tolnay M; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
Clin Cancer Res; 2014 Aug; 20(15):3902-7. PubMed ID: 24824310
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Al-Sawaf O; Zhang C; Jin HY; Robrecht S; Choi Y; Balasubramanian S; Kotak A; Chang YM; Fink AM; Tausch E; Schneider C; Ritgen M; Kreuzer KA; Chyla B; Paulson JN; Pallasch CP; Frenzel LP; Peifer M; Eichhorst B; Stilgenbauer S; Jiang Y; Hallek M; Fischer K
Nat Commun; 2023 Apr; 14(1):2147. PubMed ID: 37072421
[TBL] [Abstract][Full Text] [Related]
3. Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy.
Al-Sawaf O; Fischer K; Engelke A; Pflug N; Hallek M; Goede V
Drug Des Devel Ther; 2017; 11():295-304. PubMed ID: 28182141
[TBL] [Abstract][Full Text] [Related]
4. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.
Kater AP; Owen C; Moreno C; Follows G; Munir T; Levin MD; Benjamini O; Janssens A; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Ysebaert L; Qin R; Steele AJ; Schuier N; Baeten K; Caces DB; Niemann CU
NEJM Evid; 2022 Jul; 1(7):EVIDoa2200006. PubMed ID: 38319255
[TBL] [Abstract][Full Text] [Related]
5. Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab.
Smolej L
Pharmgenomics Pers Med; 2015; 8():1-7. PubMed ID: 25691812
[TBL] [Abstract][Full Text] [Related]
6. Serum sickness reaction to obinutuzumab in a patient with chronic lymphocytic leukaemia.
Elmanaseer O; Avelino ARM; Azem A; Raval M
BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34937753
[TBL] [Abstract][Full Text] [Related]
7. HPLC-UV and GC-MS Methods for Determination of Chlorambucil and Valproic Acid in Plasma for Further Exploring a New Combined Therapy of Chronic Lymphocytic Leukemia.
Lipska K; Gumieniczek A; Pietraś R; Filip AA
Molecules; 2021 May; 26(10):. PubMed ID: 34068372
[TBL] [Abstract][Full Text] [Related]
8. Frequency and outcomes of obinutuzumab-induced thrombocytopenia.
Ng JY; Joshi M; Choi P
Br J Haematol; 2023 Nov; 203(4):668-672. PubMed ID: 37853574
[TBL] [Abstract][Full Text] [Related]
9. New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals.
Stancu AL; Smith MR; Almasan A
Discoveries (Craiova); 2014; 2(1):. PubMed ID: 26280017
[TBL] [Abstract][Full Text] [Related]
10. Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Al-Sawaf O; Zhang C; Jin HY; Robrecht S; Choi Y; Balasubramanian S; Kotak A; Chang YM; Fink AM; Tausch E; Schneider C; Ritgen M; Kreuzer KA; Chyla B; Paulson JN; Pallasch CP; Frenzel LP; Peifer M; Eichhorst B; Stilgenbauer S; Jiang Y; Hallek M; Fischer K
Nat Commun; 2023 Oct; 14(1):6724. PubMed ID: 37872229
[No Abstract] [Full Text] [Related]
11. Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia.
Fleck C; Karabinos A; Cook A; Moore DC; Jacobs R
Leuk Lymphoma; 2024 Apr; ():1-2. PubMed ID: 38646879
[No Abstract] [Full Text] [Related]
12. Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.
Shah A
Ann Pharmacother; 2014 Oct; 48(10):1356-61. PubMed ID: 25037849
[TBL] [Abstract][Full Text] [Related]
13. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
[TBL] [Abstract][Full Text] [Related]
14. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.
Cartron G; de Guibert S; Dilhuydy MS; Morschhauser F; Leblond V; Dupuis J; Mahe B; Bouabdallah R; Lei G; Wenger M; Wassner-Fritsch E; Hallek M
Blood; 2014 Oct; 124(14):2196-202. PubMed ID: 25143487
[TBL] [Abstract][Full Text] [Related]
15. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Ladyzynski P; Molik M; Foltynski P
Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.
Byrd JC; Flynn JM; Kipps TJ; Boxer M; Kolibaba KS; Carlile DJ; Fingerle-Rowson G; Tyson N; Hirata J; Sharman JP
Blood; 2016 Jan; 127(1):79-86. PubMed ID: 26472752
[TBL] [Abstract][Full Text] [Related]
17. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.
Brown JR; O'Brien S; Kingsley CD; Eradat H; Pagel JM; Lymp J; Hirata J; Kipps TJ
Blood; 2015 Apr; 125(18):2779-85. PubMed ID: 25769620
[TBL] [Abstract][Full Text] [Related]
18. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Zelenetz AD; Barrientos JC; Brown JR; Coiffier B; Delgado J; Egyed M; Ghia P; Illés Á; Jurczak W; Marlton P; Montillo M; Morschhauser F; Pristupa AS; Robak T; Sharman JP; Simpson D; Smolej L; Tausch E; Adewoye AH; Dreiling LK; Kim Y; Stilgenbauer S; Hillmen P
Lancet Oncol; 2017 Mar; 18(3):297-311. PubMed ID: 28139405
[TBL] [Abstract][Full Text] [Related]
19. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
[TBL] [Abstract][Full Text] [Related]
20. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.
Hillmen P; Robak T; Janssens A; Babu KG; Kloczko J; Grosicki S; Doubek M; Panagiotidis P; Kimby E; Schuh A; Pettitt AR; Boyd T; Montillo M; Gupta IV; Wright O; Dixon I; Carey JL; Chang CN; Lisby S; McKeown A; Offner F;
Lancet; 2015 May; 385(9980):1873-83. PubMed ID: 25882396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]